Skip to main content

Table 1 Characteristics of patients enrolled in the study

From: Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients

Characteristic Placebo group (n = 106) Probiotic group (n = 102)
Age (years; median [range]) 57 (18–80) 60 (18–91)
Sex (male/female) 81/25a 65/37a
SAPS II score (mean ± SD) 44.2 ± 15.3 44.6 ± 16.0
Stay (days; median [range]) 13.5 (3–88) 14.0 (3–91)
Gastric tube (days; median [range]) 11.0 (2–88) 12.0 (1–90)
Urinary tract catheter (days; median [range]) 13.0 (3–88) 14.0 (2–90)
Tracheal intubation (nb/days; median [range]) 100/9.0 (1–88) 96/12.0 (1–90)
Ventilatory assistance (nb/days; median [range]) 103/13.0 (3–88) 99/14.0 (2–90)
Vascular catheter (nb/days; median [range]) 105/14.0 (3–88) 100/14.5 (2–90)
Antibiotic treatment 105 101
Antipseudomonas drugs (n; ceftazidime and/or imipenem and/or ciprofloxacin) 43 55
Fluconazole (n) 26a 45a
  1. aP < 0.05. bThe total number is indicated for characteristic when different from 106 and 102 for the placebo and the probiotic group, respectively. SAPS, Simplified Acute Physiology Score; SD, standard deviation.